Recent Updates
Recently added Catalysts

Ziprasidone

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Apr 20, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials2
Total Enrollment94

FDA Designations

No designations recorded

Clinical trial landscape

Ziprasidone · 2 trials · 1 indication

Phase 1 2
NCT01581866Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting ConditionsHealthy
COMPLETED56 Analytics
NCT01581879Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed ConditionsHealthy
COMPLETED38 Analytics
PHASE1COMPLETED
Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions
HealthyUnlock trial analytics
PHASE1COMPLETED
Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Area under curve (AUC)
1, 2, 3, 3.50, 4, 4.50, 5, 5.50, 6, 6.50, 7, 8, 9, 10, 12, 16, 24 and 36 hours post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Ziprasidone HCL Capsules, 20 mgEXPERIMENTALZiprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
Geodon Capsules, 20 mgEXPERIMENTALGeodon Capsules, 20 mg of Pfizer Inc

Interventions

NameTypeDescription
Ziprasidone HydrochlorideDRUGZiprasidone HCL Capsules, 20 mg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female, smoker or non-smoker, 18 years of age and older. * Capable of consent. * BMI between 19.0 and 30.0 kg/m2 inclusively. Exclusion Criteria: * Clinically significant illnesses within 4 weeks prior to the administration of the study medication. * Clinically signi...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Ziprasidone

What is Ziprasidone used for?

Ziprasidone is an investigational small molecule being studied in healthy volunteers. It is being developed by Dr. Reddy's Laboratories Ltd for use in bioequivalence studies, which compare the pharmacokinetics of the drug under fasting and fed conditions. The drug is currently in Phase 1 clinical development.

Who makes Ziprasidone?

Ziprasidone is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company traded under the ticker symbol RDY. The company is conducting Phase 1 bioequivalence studies of Ziprasidone HCL capsules in healthy volunteers in the United States.

What phase is Ziprasidone in?

Ziprasidone is in Phase 1 clinical development. Two Phase 1 bioequivalence studies have been completed, with a total of 94 healthy volunteers enrolled. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials is Ziprasidone in?

Ziprasidone has two completed Phase 1 clinical trials: NCT01581866, a bioequivalence study of Ziprasidone HCL capsules 20 mg under fasting conditions with 56 participants, and NCT01581879, a similar study under fed conditions with 38 participants. Both trials were conducted in the United States with healthy volunteers aged 18 years and older.

Is Ziprasidone the same as ziprasidone hydrochloride?

Ziprasidone is the generic name for the drug, and the clinical trials study Ziprasidone HCL (hydrochloride) capsules. The active ingredient is ziprasidone, and the HCL form is the salt used in the capsule formulation. Both names refer to the same drug substance.